CGM Evaluation of Glucose Excursions in Basal Insulin Treated T2DM at Fasting Glucose Target
| Status: | Completed |
|---|---|
| Conditions: | Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/30/-0001 |
| Start Date: | February 2012 |
| End Date: | October 2012 |
| Contact: | Gary S Wolfe, RN |
| Email: | gwolfe@diabetescarecenter.com |
| Phone: | 831-769-9355 |
This is a trial to determine if patients who are well controlled and on basal insulin are
treated with excessive basal dose.
In many clinical trials, basal insulin is titrated to only a fasting glucose goal. The
usual final dose is >0.4U/kg. In carefully CGM monitored/titrated studies in both basal
insulin alone or in pump-treated T2DM, we have found the basal insulin dose to be <0.3U/kg.
This suggests that if guided by a single daily fasting glucose, titration may result in an
excessive basal dose. This study will examine that issue.
Inclusion Criteria:
- Type 2 diabetes
- Age 18 years and above
- Concurrently on +/-thiazolidnedione +/-DDP IV inhibitors +/-metformin +/-
glinides and basal insulin analogs
- A1C 10% or below
- Capable of self monitoring glucose at least 4 x a day
- Previously compliant with clinical recommendations
- Fasting blood glucose <110mg/dl average for 3 consecutive days
- BMI <45 kg/m
Exclusion Criteria:
- Urinary ketosis
- Current or expected alternation in insulin sensitivity such as major surgery,
infection, renal failure, glucocorticoid treatment, recent serious hypoglycaemic
episode
- Currently participating in another clinical trial
- Using rapid insulin insulin
- Pregnancy or nursing or the intention of becoming pregnant or not using adequate
birth control
- Significant liver or heart failure.
We found this trial at
1
site
Click here to add this to my saved trials
